Vaisala’s Q4’25 figures and FY’26 guidance came in largely as expected.
Q4 results came in below expectations but showed slight y/y improvement.
Solteq returned to organic growth in Q4, but profitability remained weak.
Redeye sees Safeture’s Q4 2025 report to be another step in the right direction, with positive ARR g...
Redeye provides an update following Acarix’s Q4 2025 report.
Relais Q4 adjusted EBITA of EUR 10.8m was up 2% y/y and came 16% below LSEG Data & Analytics consens...
* Sales in line, adj. EBITA +1% vs. FactSet consensus * Return to organic growth after 10 quarters, ...
Redeye views BeammWave's Q4 2025 report as a positive read, with the share price likely to respond f...
Sales delivered relatively in line, but the star of the show was the excellent EBIT margin of 25%, t...
CEO Joakim Nydemark discusses the year-end report and the events of the past year, business model, o...
Redeye comments on Lytix' third quarter report 2025.
Atria's Q4 adjusted EBIT came in slightly below LSEG Data & Analytics consensus, driven by ASF- rela...
CapMan's Q4 top-line figures and profitability came in above our expectations.
Redeye provides an update following Neola Medical’s Q4 2025 report.
Redeye updates on W5 Solutions following Q4 results that exceeded expectations.
Redeye keeps its positive view of Vertiseit following a decent Q4 report.
Redeye retains its positive view of Lime following the Q4 report.
In Q4, CapMan performed in the areas that matter. The company raised around EUR 340m during the quar...
Verkkokauppa.com is in a positive position, with sales growth picking up, while the cost base is now...
Q4 adjusted EBITDA was in line with our estimate, but adjustments burdened net results.
